暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
自选模拟交易
美股市场个股详情
ABVC ABVC BioPharma
- 0.5488
- -0.0011-0.20%
收盘价 11/22 16:00 (美东)
- 0.5340
- -0.0148-2.70%
盘后 20:02 (美东)
712.10万总市值-677市盈率TTM
0.5732最高价0.5310最低价4.86万股成交量0.5690今开0.5499昨收2.66万成交额0.48%换手率亏损市盈率(静)1297.55万总股本2.450052周最高0.85市净率555.77万流通值0.405352周最低--股息TTM1012.70万流通股116.9000历史最高--股息率TTM7.67%振幅0.4053历史最低0.5480平均价1股每手
全部分时
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
资金分布
单位: --
资金流向
实时日周月
暂无数据
新闻
ABVC BioPharma 第三季度收入 $389,276 >ABVC3
ABVC生物制药第三季度营收$389,276 > ABVC3
快讯 | ABVC生物制药公司发布2024年第三季度财务结果和运营里程碑
ABVC BioPharma | 10-Q：2024财年三季报
ABVC生物制药公司获得5万美元的增量许可费，将其三个战略合作伙伴的总付款提升至34.6万美元
加州弗里蒙特，2024年10月22日 (环球新闻社) -- ABVC生物制药公司 (纳斯达克:ABVC)，一家专注于眼科医疗、中枢神经系统和创新治疗的临床阶段生物制药公司。
12只医疗保健股票在周二盘后交易中上涨
涨幅领先者拜欧迪雅制药（纳斯达克：BDRX）股票在周二盘后交易中上涨了119.0%，至10.6美元。其流通股市值为15390万美元。彼得斯
快讯 | ABVC生物制药- 收到纳斯达克发来的书面通知，表示公司已恢复符合5635(a)(1)和5635(a)(2)的上市规则。
评论
$ABVC BioPharma (ABVC.US)$
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
ABVC BioPharma has received an additional $50,000 in licensing fees from AiBtl BioPharma Inc., bringing the total payments from strategic partners to $346,000. This payment is part of a broader agreement related to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder (MDD) and Attention Deficit ...
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
ABVC BioPharma has received an additional $50,000 in licensing fees from AiBtl BioPharma Inc., bringing the total payments from strategic partners to $346,000. This payment is part of a broader agreement related to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder (MDD) and Attention Deficit ...
已翻译
2
$ABVC BioPharma (ABVC.US)$ Financial Performance:
- Earnings Per Share (EPS): Demonstrated a remarkable year-over-year improvement of approximately 86.8%, with EPS improving to -$0.09 in Q2 2024 from -$0.68 in the same period last year. This significant progress reflects our successful efforts in managing operational expenses and capitalizing on milestone payment revenue from licensing agreements.
- Revenue Growth: Revenue increased to $117,142 in Q2 2024, a substantial rise from $6,109...
- Earnings Per Share (EPS): Demonstrated a remarkable year-over-year improvement of approximately 86.8%, with EPS improving to -$0.09 in Q2 2024 from -$0.68 in the same period last year. This significant progress reflects our successful efforts in managing operational expenses and capitalizing on milestone payment revenue from licensing agreements.
- Revenue Growth: Revenue increased to $117,142 in Q2 2024, a substantial rise from $6,109...
1
阅读更多
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
暂无数据
周淮安 : 你认为这里会发生什么？
Jaguar8 楼主 周淮安 : 目前没有成交量